[
  {
    "ts": null,
    "headline": "5 Revealing Analyst Questions From Charles River Laboratories’s Q1 Earnings Call",
    "summary": "Charles River Laboratories’ first quarter drew a highly positive market response, with results driven by stronger-than-expected demand in its Drug Safety Assessment (DSA) segment and signs of stabilization across client groups. Management credited improved bookings and a net book-to-bill ratio above 1x for the DSA segment, noting this was the first such result in over two years. CEO Jim Foster highlighted, “We were pleased to see the DSA net book-to-bill return to just above 1x for the first tim",
    "url": "https://finnhub.io/api/news?id=85858f82dd036bc21be96401a29598835aff11bf3ba4d28e2ce0fc410eb2ca06",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751607070,
      "headline": "5 Revealing Analyst Questions From Charles River Laboratories’s Q1 Earnings Call",
      "id": 135760017,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CRL",
      "source": "Yahoo",
      "summary": "Charles River Laboratories’ first quarter drew a highly positive market response, with results driven by stronger-than-expected demand in its Drug Safety Assessment (DSA) segment and signs of stabilization across client groups. Management credited improved bookings and a net book-to-bill ratio above 1x for the DSA segment, noting this was the first such result in over two years. CEO Jim Foster highlighted, “We were pleased to see the DSA net book-to-bill return to just above 1x for the first tim",
      "url": "https://finnhub.io/api/news?id=85858f82dd036bc21be96401a29598835aff11bf3ba4d28e2ce0fc410eb2ca06"
    }
  }
]